{"id":25392,"date":"2024-04-03T14:51:12","date_gmt":"2024-04-03T14:51:12","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=25392"},"modified":"2025-12-01T14:57:10","modified_gmt":"2025-12-01T13:57:10","slug":"crispr-cas13-2","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/es\/crispr-cas13-2\/","title":{"rendered":"CRISPR-Cas13"},"content":{"rendered":"<p><strong>Una tecnolog\u00eda revolucionaria de alto potencial para el s\u00edndrome de duplicaci\u00f3n del gen MECP2 <\/strong><\/p>\n\n<p>La tecnolog\u00eda CRISPR ha revolucionado el mundo de la ingenier\u00eda gen\u00e9tica. Entre los distintos tipos de sistemas CRISPR, el CRISPR-Cas13 destaca por su capacidad \u00fanica de dirigirse al ARN mensajero, a diferencia de otros sistemas que se dirigen al ADN. Este art\u00edculo explora la tecnolog\u00eda CRISPR-Cas13 y su posible aplicaci\u00f3n en el tratamiento del s\u00edndrome de duplicaci\u00f3n del gen MECP2.<\/p>\n\n<p><strong>CRISPR-Cas13: breve resumen<\/strong><\/p>\n\n<p>CRISPR-Cas13 forma parte del sistema CRISPR, una herramienta revolucionaria que ha transformado el campo de la ingenier\u00eda gen\u00e9tica. CRISPR-Cas13 es \u00fanico porque se dirige a mol\u00e9culas de ARN mensajero, los intermediarios entre el ADN y las prote\u00ednas. Esto permite un enfoque m\u00e1s din\u00e1mico y reversible de la modificaci\u00f3n gen\u00e9tica, ya que las modificaciones realizadas en el ARN no alteran permanentemente el genoma.<\/p>\n\n<p>La prote\u00edna Cas13 es una endonucleasa guiada por ARN que destruye mol\u00e9culas de ARN. Puede programarse con ARN gu\u00eda para atacar y cortar cualquier secuencia de ARN, lo que la convierte en una herramienta vers\u00e1til para la investigaci\u00f3n gen\u00e9tica y posibles aplicaciones terap\u00e9uticas.<\/p>\n\n<p><strong>El papel del AAV en la administraci\u00f3n de CRISPR-Cas13<\/strong><\/p>\n\n<p>En el contexto del s\u00edndrome de duplicaci\u00f3n MECP2, un componente esencial del sistema CRISPR-Cas13 es el vector utilizado para su administraci\u00f3n: el virus adenoasociado (AAV). Los AAV son vectores muy utilizados en terapia g\u00e9nica por su capacidad de administrar genes a las c\u00e9lulas con una respuesta inmunitaria m\u00ednima. En el caso de CRISPR-Cas13, el vector AAV se utiliza para introducir la prote\u00edna Cas13 y su ARN gu\u00eda en las c\u00e9lulas. Esto permite al sistema alcanzar las mol\u00e9culas de ARN objetivo y llevar a cabo su funci\u00f3n de corte.<\/p>\n\n<p><strong>Administraci\u00f3n de f\u00e1rmacos<\/strong><\/p>\n\n<p>Para lograr una mayor biodisponibilidad, el f\u00e1rmaco se administra directamente en el cerebro. Este m\u00e9todo garantiza que una mayor concentraci\u00f3n del f\u00e1rmaco llegue al lugar de destino, lo que aumenta su eficacia.<\/p>\n\n<p><strong>CRISPR-Cas13 en el s\u00edndrome de duplicaci\u00f3n del gen MECP2<\/strong><\/p>\n\n<p>El potencial de CRISPR-Cas13 en el tratamiento del s\u00edndrome de duplicaci\u00f3n del gen MECP2 reside en su capacidad para dirigirse y degradar el ARNm MECP2 extra producido como resultado de la duplicaci\u00f3n del gen. Al reducir los niveles de prote\u00edna MECP2, podr\u00eda aliviar potencialmente los s\u00edntomas del s\u00edndrome.<\/p>\n\n<p><strong>Conclusi\u00f3n<\/strong><\/p>\n\n<p>CRISPR-Cas13 representa una herramienta prometedora para el tratamiento de trastornos gen\u00e9ticos como el s\u00edndrome de duplicaci\u00f3n.<em> <\/em>del gen MECP2. Al atacar la ra\u00edz del trastorno a nivel del ARN, ofrece una posible estrategia terap\u00e9utica que podr\u00eda mejorar la vida de los pacientes. M\u00e1s all\u00e1 del s\u00edndrome de duplicaci\u00f3n de MECP2, las aplicaciones potenciales de CRISPR-Cas13 son amplias, incluido el tratamiento de otros trastornos neurol\u00f3gicos como la enfermedad de Alzheimer, el s\u00edndrome de Angelman*, etc. <\/p>\n\n<p><em>*Jinhui Li, Hui Yang. A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice. Molecular Therapy. 5 de julio de 2023; 31 (7): 2286-2295.<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Une technologie r\u00e9volutionnaire \u00e0 haut potentiel dans le syndrome de duplication du g\u00e8ne MECP2 Le monde du g\u00e9nie g\u00e9n\u00e9tique a \u00e9t\u00e9 r\u00e9volutionn\u00e9 par l&rsquo;av\u00e8nement de la technologie CRISPR. Parmi les [&hellip;]<\/p>","protected":false},"author":1,"featured_media":4720,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-25392","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CRISPR-Cas13 - DupMECP2<\/title>\n<meta name=\"description\" content=\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l&#039;ARN messager, contrairement \u00e0 d&#039;autres syst\u00e8mes qui ciblent l&#039;ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/es\/crispr-cas13-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR-Cas13 - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l&#039;ARN messager, contrairement \u00e0 d&#039;autres syst\u00e8mes qui ciblent l&#039;ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/es\/crispr-cas13-2\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-03T14:51:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T13:57:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1637\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"CRISPR-Cas13\",\"datePublished\":\"2024-04-03T14:51:12+00:00\",\"dateModified\":\"2025-12-01T13:57:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"},\"wordCount\":531,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\",\"url\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\",\"name\":\"CRISPR-Cas13 - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"datePublished\":\"2024-04-03T14:51:12+00:00\",\"dateModified\":\"2025-12-01T13:57:10+00:00\",\"description\":\"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l'ARN messager, contrairement \u00e0 d'autres syst\u00e8mes qui ciblent l'ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg\",\"width\":2560,\"height\":1637},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CRISPR-Cas13\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/es\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR-Cas13 - DupMECP2","description":"Entre los distintos tipos de sistemas CRISPR, el CRISPR-Cas13 destaca por su capacidad \u00fanica de dirigirse al ARN mensajero, a diferencia de otros sistemas que se dirigen al ADN. Este art\u00edculo explora la tecnolog\u00eda CRISPR-Cas13 y su posible aplicaci\u00f3n en el tratamiento del s\u00edndrome de duplicaci\u00f3n del gen MECP2.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/es\/crispr-cas13-2\/","og_locale":"es_ES","og_type":"article","og_title":"CRISPR-Cas13 - DupMECP2","og_description":"Parmi les diff\u00e9rents types de syst\u00e8mes CRISPR, le CRISPR-Cas13 se distingue par sa capacit\u00e9 unique \u00e0 cibler l'ARN messager, contrairement \u00e0 d'autres syst\u00e8mes qui ciblent l'ADN. Cet article explore la technologie CRISPR-Cas13 et son application potentielle dans le traitement du syndrome de duplication du g\u00e8ne MECP2.","og_url":"https:\/\/dupmecp2.eu\/es\/crispr-cas13-2\/","og_site_name":"DupMECP2","article_published_time":"2024-04-03T14:51:12+00:00","article_modified_time":"2025-12-01T13:57:10+00:00","og_image":[{"width":2560,"height":1637,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Caroline","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"CRISPR-Cas13","datePublished":"2024-04-03T14:51:12+00:00","dateModified":"2025-12-01T13:57:10+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/"},"wordCount":531,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/","url":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/","name":"CRISPR-Cas13 - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","datePublished":"2024-04-03T14:51:12+00:00","dateModified":"2025-12-01T13:57:10+00:00","description":"Entre los distintos tipos de sistemas CRISPR, el CRISPR-Cas13 destaca por su capacidad \u00fanica de dirigirse al ARN mensajero, a diferencia de otros sistemas que se dirigen al ADN. Este art\u00edculo explora la tecnolog\u00eda CRISPR-Cas13 y su posible aplicaci\u00f3n en el tratamiento del s\u00edndrome de duplicaci\u00f3n del gen MECP2.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/crispr-cas13-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2022\/08\/Research-1-scaled.jpg","width":2560,"height":1637},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/crispr-cas13-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"CRISPR-Cas13"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"UE","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/es\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts\/25392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/comments?post=25392"}],"version-history":[{"count":1,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts\/25392\/revisions"}],"predecessor-version":[{"id":33396,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts\/25392\/revisions\/33396"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/media\/4720"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/media?parent=25392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/categories?post=25392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/tags?post=25392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}